BidaskClub upgraded shares of Opko Health, Inc. (NASDAQ:OPK) from a sell rating to a hold rating in a research report sent to investors on Saturday.

OPK has been the subject of several other research reports. Cantor Fitzgerald began coverage on shares of Opko Health in a research note on Thursday, August 17th. They issued an overweight rating and a $20.00 target price for the company. Jefferies Group LLC reiterated a hold rating and issued a $8.00 target price on shares of Opko Health in a research note on Monday, June 12th. Zacks Investment Research upgraded shares of Opko Health from a hold rating to a buy rating and set a $7.25 target price for the company in a research note on Friday, July 21st. Barrington Research lifted their target price on shares of Opko Health to $11.00 and gave the stock an outperform rating in a research note on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services reiterated a buy rating and issued a $19.50 target price on shares of Opko Health in a research note on Tuesday, June 6th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Opko Health has an average rating of Buy and an average price target of $14.36.

Shares of Opko Health (NASDAQ:OPK) traded up 3.55% during mid-day trading on Friday, hitting $6.71. 7,434,932 shares of the company traded hands. The stock’s market capitalization is $3.75 billion. Opko Health has a one year low of $5.85 and a one year high of $12.15. The firm has a 50-day moving average of $6.19 and a 200-day moving average of $6.84.

Opko Health (NASDAQ:OPK) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million during the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The company’s revenue was down 12.0% on a year-over-year basis. During the same quarter last year, the company earned $0.02 earnings per share. On average, equities analysts predict that Opko Health will post ($0.19) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/24/opko-health-inc-opk-upgraded-by-bidaskclub-to-hold.html.

In other news, CEO Phillip Md Et Al Frost acquired 60,800 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was bought at an average cost of $6.44 per share, for a total transaction of $391,552.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $19,764,044.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 1,106,800 shares of company stock valued at $6,822,041 over the last 90 days. 40.19% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. Credit Suisse AG raised its stake in shares of Opko Health by 122.0% during the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock worth $5,976,000 after acquiring an additional 410,445 shares in the last quarter. State Street Corp raised its stake in shares of Opko Health by 40.3% during the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after acquiring an additional 3,138,685 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD raised its stake in shares of Opko Health by 14.8% during the second quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock worth $910,000 after acquiring an additional 17,458 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Opko Health during the first quarter worth approximately $4,450,000. Finally, State Board of Administration of Florida Retirement System raised its stake in shares of Opko Health by 7.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock worth $2,634,000 after acquiring an additional 27,940 shares in the last quarter. Institutional investors and hedge funds own 22.46% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.